Nadolol
- Atc Codes:C07AA12
- CAS Codes:42200-33-9
- PHARMGKB ID:42200-33-9
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Substrate of
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
France: Corgard; Poland: Apo-Nadol; Spain: Solgol; UK: Corgard.
North America
Canada: Apo-Nadol, Nadolol; USA: Corgard, Nadolol.
Latin America
Brazil: Corgard; Mexico: Corgard.
Asia
Japan: Nadic.
Drug combinations
Nadolol and Bendroflumethiazide
Chemistry
Nadolol: C~17~H~27~NO~4~. Mw: 309.40. (1) 2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro-, cis-; (2) 1-(tert-Butylamino)-3-[(5,6,7,8-tetrahydro-cis-6,7-dihydroxy-1-naphthyl)oxy]-2-propanol. CAS-42200-33-9 (1976).
Pharmacologic Category
Cardiovascular Drugs; β-Adrenergic Blocking Agents. Nonselective β-Adrenergic Blocker. (ATC-Code: C07AA12).
Mechanism of action
Competitively blocks response to β~1~- and β~2~-adrenergic stimulation.
Therapeutic use
Treatment of hypertension and angina pectoris. Prophylaxis of migraine headaches.
Pregnancy and lactiation implications
No data available to date on crossing placenta. β-Blockers associated with bradycardia, hypotension, and intrauterine growth retardation. Alternative β-blockers preferred for use during pregnancy. Cases of neonatal hypoglycemia reported. Enters breast milk (use with caution in nursing women).
Unlabeled use
Contraindications
Hypersensitivity to nadolol. Bronchial asthma, sinus bradycardia, sinus node dysfunction, heart block greater than first degree, cardiogenic shock, uncompensated cardiac failure.
Warnings and precautions
Use caution with history of severe anaphylaxis to allergens. In general, patients with bronchospastic disease should not receive β-blockers. Use with caution in diabetes mellitus (may potentiate hypoglycemia), in compensated heart failure, in myasthenia gravis, and in peripheral vascular disease. May cause or exacerbate CNS depression in history of psychiatric illness. Use with caution in renal impairment, in patients receiving anesthetic agents which decrease myocardial function, or on concurrent verapamil or diltiazem (bradycardia or heart block can occur). β-Blocker therapy should not be withdrawn abruptly.